Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Inland Real Estate Reveals JV Acquisition Of Seven Properties - Quick Facts

RELATED NEWS
Trade IRC now with 

Inland Real Estate Corp. (IRC: Quote) said Monday it has contributed $15 million to its joint venture with Inland Private Capital Corp. to acquire for $40.8 million two portfolios that include seven single-tenant retail properties.

The company said the joint venture acquired a portfolio of two free-standing stores net leased to CVS Pharmacy and one asset that is net leased to Walgreens, for a purchase price of $17.1 million. The venture also acquired for $23.7 million a second portfolio which includes one asset that is net leased to CVS, plus three properties that are net leased to Walgreens.

Simultaneous with the closing, the joint venture placed loans totaling $25.8 million on the portfolios, the company said.

Click here to receive FREE breaking news email alerts for Inland Real Estate Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After turning in a lackluster performance for much of the session, stocks managed to end Wednesday's trading mostly higher. The gains lifted the Dow and the S&P 500 to new record closing highs, while the Nasdaq reached its best levels since 2000. Half of Americans agree with the changes to immigration policy announced by President Barack Obama last week, according to a CNN/ORC poll, although a majority opposes using executive orders to implement those policies. While Mitt Romney has said he has no plans to run for president again, the results of a Quinnipiac University national poll released Wednesday show the former Massachusetts Governor leading a group of potential Republican presidential candidates.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.